Supplier
Florida Health Sciences Center INC
Florida Health Sciences Center INC was paid $339K by Medicaid between Jan 2018 and Nov 2024, across 8 billing codes. Its largest line is J7503, Tacrolimus, extended release, (envarsus xr), oral, 0.25 mg — 52% of everything it billed.
33Billing provider infoFLORIDA HEALTH SCIENCES CENTER INC
TAMPA, FL 33610
TAMPA, FL 33610
33aNPI1699836205assigned 12/13/2006
33bProvider typePharmacy
28Total paid$339K
24GClaims97,153
24DCodes billed8
24AFirst – last monthJan 2018 – Nov 2024
Compared with peers
Next to other Pharmacy providers in Florida
Rank by total paid#3 of 77
Median peer was paid$18.84
This provider vs. median17,995×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 7,276 | $31K | |
| 2019 | 10,716 | $54K | |
| 2020 | 15,265 | $67K | |
| 2021 | 18,883 | $69K | |
| 2022 | 18,269 | $38K | |
| 2023 | 16,340 | $49K | |
| 2024incomplete | 10,404 | $32K |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| J7503 | Tacrolimus, extended release, (envarsus xr), oral, 0.25 mg | 52% | 10,424 | 4,863 | $175K |
| J7518 | Mycophenolic acid, oral, 180 mg | 20% | 5,053 | 3,735 | $69K |
| J7517 | Mycophenolate mofetil, oral, 250 mg | 13% | 10,213 | 7,330 | $45K |
| J7507 | Tacrolimus, immediate release, oral, 1 mg | 13% | 12,584 | 7,518 | $43K |
| J7512 | Prednisone, immediate release or delayed release, oral, 1 mg | <1% | 10,355 | 7,578 | $3K |
| Q0511 | Pharmacy supply fee for oral anti-cancer, oral anti-emetic or immunosuppressive drug(s); for the first prescription in a 30-day period | <1% | 15,913 | 12,331 | $2K |
| Q0512 | Pharmacy supply fee for oral anti-cancer, oral anti-emetic or immunosuppressive drug(s); for a subsequent prescription in a 30-day period | <1% | 32,599 | 12,997 | $1K |
| A4215 | Needle, sterile, any size, each | <1% | 12 | 12 | $190.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialGIFT, MAJA (DIRECTOR OF PHARMACY/AO)